LeserbriefKommentar
Tofacitinib in Ulcerative Colitis: Beyond Biologics?
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad308 ↗Kurz gefasst
Leserbrief in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Prajna Anirvan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Kalinga Gastroenterology Foundation, Cuttack, India. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products, Pyrimidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Colitis, UlcerativeBiological ProductsPyrimidinesHumansBiological FactorsPiperidines
Substanzen
Biological ProductstofacitinibBiological FactorsPiperidinesPyrimidines
Autor:innen und Institutionen
- Kalinga Gastroenterology Foundation, Cuttack, India.
- Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar, India.
ORCID-Profile: Suprabhat Giri
Zitieren
APA
Anirvan, P., & Giri, S. (2024). Tofacitinib in Ulcerative Colitis: Beyond Biologics?. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad308
Vancouver
Anirvan P, Giri S. Tofacitinib in Ulcerative Colitis: Beyond Biologics?. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad308
BibTeX
@article{Anirvan2024,
author = {Anirvan, Prajna and Giri, Suprabhat},
title = {Tofacitinib in Ulcerative Colitis: Beyond Biologics?},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad308}
}
EUVIMED